Azenta Plans $11 Million to $13 Million Restructuring Charge, Closing Three Multiomics Labs
Azenta said its board approved a restructuring plan on October 5, 2026, to consolidate its North American laboratory network, cut workforce and close three Multiomics sites in North America. The company estimates $11.0 million to $13.0 million in pre-tax charges, mostly non-cash impairments, with about $7.0 million in future cash spending and about $11.0 million in annualized savings once fully implemented.
Key points
- Plan approved October 5, 2026, within the Multiomics segment; employee notifications began October 6, 2026
- Estimated pre-tax charges of $11.0 million to $13.0 million, including about $9.0 million of asset impairment and about $3.0 million of severance and other restructuring
- Estimated future cash expenditures of about $7.0 million; expected annualized cost savings of about $11.0 million
- Most charges expected in the fiscal year ending September 30, 2027; actions substantially complete by March 31, 2027
The filing
Written by AI on Nov 8, 2026, 1:55 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 07, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.